Federal marijuana rescheduling took effect on April 23, 2026, when the Department of Justice and the Drug Enforcement Administration moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act.1Department of Justice. Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Regulated by State Medical Marijuana Licenses in Schedule III Recreational marijuana was not included and remains a Schedule I substance under federal law. It is the first change to marijuana’s federal classification since the scheduling system was created in 1970.
What the Order Covers and What It Leaves Out
The April 2026 order is narrower than many headlines have suggested. Two categories moved to Schedule III: products with full FDA approval, and marijuana manufactured, distributed, or dispensed under a state medical marijuana license.1Department of Justice. Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Regulated by State Medical Marijuana Licenses in Schedule III Everything else stayed put.
That means recreational marijuana is still Schedule I. Synthetic THC that sits outside an FDA-approved product or state medical license is also still Schedule I. Two people dealing in chemically identical products can now face very different federal consequences depending on whether the product moved through a state medical program.
The DOJ relied on 21 U.S.C. § 811(d)(1), a rarely used provision that lets the Attorney General reschedule a substance without full notice-and-comment rulemaking when the action is needed to comply with international treaty obligations under the Single Convention on Narcotic Drugs.2Office of the Law Revision Counsel. 21 USC 811 – Authority and Criteria for Classification of Substances That legal basis is why the order took effect immediately. Legal observers expect the treaty-authority theory to be challenged in court, but no ruling has been issued as of mid-2026.
Criminal Penalties Under Schedule III
The gap between Schedule I and Schedule III penalties is where rescheduling has the sharpest human impact. Federal trafficking offenses involving Schedule I substances carry mandatory minimums of five years for certain quantities and ten years for larger amounts, with maximums reaching life imprisonment.3Drug Enforcement Administration. Federal Trafficking Penalties Judges cannot go below those floors.
Schedule III has no mandatory minimums. A first trafficking offense involving a Schedule III substance carries a maximum of 10 years and a fine of up to $500,000 for an individual. A second offense after a prior felony drug conviction raises the maximum to 20 years and a $1,000,000 fine.4Office of the Law Revision Counsel. 21 USC 841 – Prohibited Acts A Federal judges get discretion back, from probation up to the statutory cap.
This reduced framework only reaches the products the April 2026 order covers. Anyone caught trafficking recreational marijuana still faces the full weight of Schedule I penalties.
Tax Relief Under Section 280E
Section 280E of the Internal Revenue Code blocks any business trafficking in a Schedule I or II controlled substance from deducting ordinary business expenses such as rent, payroll, utilities, and marketing.5Office of the Law Revision Counsel. 26 USC 280E – Expenditures in Connection With the Illegal Sale of Drugs The only deduction has been cost of goods sold. Marijuana companies have been paying federal income tax on gross profit rather than net income, and the Senate Finance Committee has estimated effective tax rates running as high as 80 percent.
Because 280E applies only to Schedules I and II, moving medical marijuana to Schedule III lifts the penalty for those operators. State-licensed medical marijuana businesses can now deduct ordinary and necessary expenses the same way any other legal business would under 26 U.S.C. § 162.6Office of the Law Revision Counsel. 26 U.S. Code 162 – Trade or Business Expenses For mid-sized operators, that can mean hundreds of thousands of dollars in annual tax savings.
When the Tax Relief Applies
Treasury and the IRS have said they will treat the rescheduling as applying to a business’s full taxable year that includes the effective date of the April 2026 order, for activities that no longer involve Schedule I or II substances as a result of that order.7Department of the Treasury. Treasury, IRS Announce Process for Tax Guidance Following DOJ Rescheduling For a fiscal year running January through December 2026, deductible expenses should cover the whole year, not just the months after April 23.
Retroactive relief for prior tax years is less clear. The rescheduling order encourages Treasury to consider relief for past-due liabilities, but no formal guidance grants full retroactivity as of mid-2026. Businesses that overpaid in earlier years should work with a tax professional before filing amended returns.
Recreational Sellers Still Pay Under 280E
Recreational marijuana remains Schedule I, so adult-use businesses continue to operate under the full 280E burden. A dispensary in a state with both medical and recreational programs may see medical sales freed from 280E while recreational sales stay non-deductible. Separating those revenue streams cleanly will be an accounting challenge, and the IRS is likely to scrutinize how expenses get allocated between the two.
The New DEA Registration Pathway
Under Schedule I, handling marijuana legally required a DEA research registration that was nearly impossible to obtain for commercial purposes. The April 2026 order creates a new route: state-licensed medical marijuana operators can register with the DEA as manufacturers, distributors, or dispensers under an expedited review.8Federal Register. Schedules of Controlled Substances: Rescheduling of FDA-Approved Products Containing Marijuana
A state medical marijuana license counts as conclusive evidence that the applicant is authorized under state law. The DEA committed to processing applications filed within 60 days of the rule’s publication inside a six-month window. Applicants who file during that 60-day window can keep operating under their state license while their federal registration is pending, which prevents the backlog from freezing the industry.8Federal Register. Schedules of Controlled Substances: Rescheduling of FDA-Approved Products Containing Marijuana
Registered entities can also follow their state’s labeling, packaging, disposal, and physical security rules instead of the standard federal Schedule III requirements. State-issued medical certifications or recommendations can substitute for traditional Schedule III prescriptions, provided they include the patient’s name and address, the practitioner’s name and state license number, and a signature dated the day of issuance.8Federal Register. Schedules of Controlled Substances: Rescheduling of FDA-Approved Products Containing Marijuana
Banking and Card Processing
Marijuana businesses have operated cash-heavy because most banks were unwilling to accept the money laundering risk of servicing Schedule I operations. FinCEN’s 2014 guidance created a narrow compliance path built on specialized suspicious activity reports, but the cost kept most institutions away.
With medical marijuana now in Schedule III, banking access is expected to improve as anti-money-laundering exposure recedes. FinCEN is widely expected to update its 2014 guidance, which would simplify reporting for banks working with medical marijuana clients. That updated guidance has not been issued as of mid-2026.
Credit cards are a harder problem. Visa and Mastercard both prohibit cannabis transactions involving plant-touching products, and neither network has changed its rules after rescheduling. Until the networks update their merchant category policies, medical marijuana businesses cannot accept credit cards through standard processing regardless of Schedule III status. Access to ACH and account-to-account bank transfers may expand, but the cash reality of the industry is not going away quickly.
The Broader Proceeding Still Pending
The immediate order was only half of what the DEA announced in April 2026. A separate administrative proceeding is considering whether to move all marijuana, including recreational, from Schedule I to Schedule III through full rulemaking.9Federal Register. Schedules of Controlled Substances: Rescheduling of Marijuana HHS completed its scientific and medical evaluation in 2023 and recommended Schedule III. The DEA published a proposed rule in May 2024 and received substantial public comment.
A formal hearing before an administrative law judge is set to begin June 29, 2026, and will examine whether the evidence supports rescheduling all marijuana.9Federal Register. Schedules of Controlled Substances: Rescheduling of Marijuana If that broader change goes through, recreational marijuana would come under the same Schedule III framework medical marijuana already occupies. The timeline for a final decision is uncertain and the outcome is not guaranteed.
What Rescheduling Does Not Do
Rescheduling is not legalization. Marijuana is still a federally controlled substance. Manufacturing, distributing, or dispensing it without proper DEA registration is still a federal crime, and no one can legally sell marijuana at the federal level without either FDA approval or a state medical license paired with DEA registration. The penalties are lower under Schedule III than they were under Schedule I, but the underlying prohibition remains.
The order also does not preempt state law. States that have legalized recreational marijuana can continue those programs, but they gain no new federal protection for doing so. States that prohibit marijuana entirely can keep prohibiting it. The federal floor shifted; each state’s ceiling is still its own choice.
For individuals, simple possession of marijuana remains a federal offense. Rescheduling changes the penalty structure, not the legality of recreational use under federal law.